US Rheumatologists Identify BAFF-R Inhibitors as the Most Promising Treatment Approach for Sjögren's Disease, According to Spherix Global Insights [Yahoo! Finance]
Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
EXTON, PA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Sjögren's disease is a systemic autoimmune rheumatic condition that can profoundly affect a patient's overall functioning. Common symptoms include significant dryness, particularly in the eyes and mouth, along with severe fatigue, chronic joint pain, neuropathy, and swelling. In more advanced cases, it can lead to complications involving major organs or even lymphoma. Sjögren's is one of the more frequently treated conditions by rheumatologists, following rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and psoriatic arthritis. The absence of FDA-approved therapies, along with the diverse range of symptoms and multiple co-morbidities, underscores the substantial unmet need for novel, targeted treatments. In August 2024, Spherix Global Insights gathered insights from 103 US rheumatologists as part of their Market Dynamix™ service to capture prescriber perspectives on the evolving treatment landscape for Sjögren's diseas
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare ConferenceGlobeNewswire
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $39.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $30.00 to $35.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio ExecutionGlobeNewswire
- Here's What Could Help Kiniksa Pharmaceuticals (KNSA) Maintain Its Recent Price Strength [Yahoo! Finance]Yahoo! Finance
KNSA
Earnings
- 10/29/24 - Miss
KNSA
Sec Filings
- 11/20/24 - Form 4
- 11/18/24 - Form 144
- 11/14/24 - Form SC
- KNSA's page on the SEC website